Success Metrics

Clinical Success Rate

66.7%

Based on 2 completed trials

Completion Rate

67%(2/3)

Active Trials

0(0%)

Results Posted

50%(1 trials)

Terminated

1(20%)

Phase Distribution

Ph phase_4

60%

Ph phase_3

40%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 3Large-scale testing

2(40.0%)

Phase 4Post-market surveillance

3(60.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(2)

Terminated(1)

Other(2)

Detailed Status

unknown2

Completed2

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

66.7%

Most Advanced

Phase 4

Trials by Phase

Phase 32 (40.0%)

Phase 43 (60.0%)

Trials by Status

terminated120%

unknown240%

completed240%

Recent Activity

0 active trials

Showing 5 of 5

completedphase_3

The Late Presenter Treatment Optimisation Study

NCT03696160

terminatedphase_4

Integrase Regimen Switch to Symtuza to Increase Tolerability/Adherence (SYMita)

NCT04240210

completedphase_3

Efficacy of BIC/F/TAF Versus Standard of Care in the Treatment of New HIV Infection Diagnoses in the Context of 'Test and Treat'

NCT04653194

unknownphase_4

Effect of Biktarvy & Symtuza on microRNAs in HIV and Correlation With Weight Gain

NCT05463783

unknownphase_4

Implication for Strategies of Long Term Control of Viral Replication in Patient With Primary HIV Infection (PHI).

NCT04225325

Clinical Trials (5)

Showing 5 of 5 trials

NCT03696160Phase 3

The Late Presenter Treatment Optimisation Study

Completed

NCT04240210Phase 4

Integrase Regimen Switch to Symtuza to Increase Tolerability/Adherence (SYMita)

Terminated

NCT04653194Phase 3

Efficacy of BIC/F/TAF Versus Standard of Care in the Treatment of New HIV Infection Diagnoses in the Context of 'Test and Treat'

Completed

NCT05463783Phase 4

Effect of Biktarvy & Symtuza on microRNAs in HIV and Correlation With Weight Gain

Unknown

NCT04225325Phase 4

Implication for Strategies of Long Term Control of Viral Replication in Patient With Primary HIV Infection (PHI).

Unknown

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5